Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 31, 2015 5:04 PM ET

Biotechnology

Company Overview of Redbiotec AG

Company Overview

Redbiotec AG develops and produces multiprotein assemblies. It specializes in producing virus-like particles (VLP), various types of protein complexes and single proteins, and VLP-based vaccines against various infectious diseases. The company’s products are used in complex drug target, structural studies, target validation, antibody generation, biopharmaceutical, and VLP applications. Redbiotec AG was founded in 2006 and is based in Schlieren, Switzerland.

Wagistrasse 23

Schlieren,  8952

Switzerland

Founded in 2006

Phone:

41 44 200 23 20

Fax:

41 44 200 23 21

Key Executives for Redbiotec AG

Chief Executive Officer and Director
Compensation as of Fiscal Year 2015.

Redbiotec AG Key Developments

Redbiotec AG Presents at BIO-Europe Spring 2015, Mar-09-2015

Redbiotec AG Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

Redbiotec and GE Healthcare Collaborate

Redbiotec has successfully applied its unique expertise and innovative technology platform to complete a collaborative program with GE Healthcare Life Sciences. Using GE Healthcare’s single-use WAVE Bioreactor and ReadyToProcess crossflow filtration system, the team developed a novel process for the production, clarification, and concentration of cytomegalovirus-like particles. Results from the study have recently been published, further substantiating the value of the Redbiotec rePAX platform for the development and production of new vaccines against cytomegalovirus (CMV). Redbiotec uses its proprietary rePAX co-expression technology for the efficient generation of multi-component virus-like particles (VLPs) and other protein assemblies. This technology is effectively applied to both in-house and external co-development programs, supporting the company’s mission to discover and develop novel, effective vaccines against the highly prevalent influenza and herpes viruses.

Redbiotec and TeselaGen Announce Joint Venture

Redbiotec and TeselaGen Biotechnology Inc. have announced a joint venture to build a scalable, integrated, rapid design and rapid prototyping infrastructure for the creation of a library for Herpesvirus vaccine development. This library will enable new concepts for vaccines against Herpesviruses and the optimization of existing vaccine candidates.

Similar Private Companies By Industry

Company Name Region
CellSpring Europe
Celgene International Sárl Europe
InSphero AG Europe
Obexia AG Europe
ImmunoGenes AG Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
January 5, 2015
Redvax GmbH
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Redbiotec AG, please visit www.redbiotec.ch. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.